Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2025-12-25 @ 4:49 PM
Study NCT ID:
NCT05296603
Status:
RECRUITING
Last Update Posted:
2024-01-10
First Post:
2022-03-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Sponsor:
Hunan Province Tumor Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-03
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-25
Completion Date Type:
ESTIMATED
First Submit Date:
2022-03-15
First Submit QC Date:
None
Study First Post Date:
2022-03-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-08
Last Update Post Date:
2024-01-10
Last Update Post Date Type:
ACTUAL